• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Case Report: A Spinal Ischemic Lesion in a 24-Year-Old Patient With Fabry Disease
ConclusionThe current case highlights the possible occurrence of spinal ischemic lesions in FD. Thus, the diagnosis of FD should not be prematurely discarded in the presence of spinal lesions.
Source: Frontiers in Immunology - December 14, 2020 Category: Allergy & Immunology Source Type: research

Anti glutamic acid decarboxylase antibody mediated encephalopathy while on etanercept in a patient with multiple autoimmune diseases
A 39 year old lady presented with an altered mental state and unsteadiness of gait. She had a history of juvenile idiopathic arthritis, autoimmune thyroiditis and alopecia, protein S deficiency with vena cava thrombosis, previous excision of ovarian mass and vasculitic rash. There was a previous history of ovarian mass and her immunomodulatory therapy for arthritis over the previous year was Etanercept. She used recreational cannabis but denied any other illicit drug usage. Her affect was variable and at times inappropriate with frequent laughter. She would spit regularly. There was anxiety and a prevailing sensation of do...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: MacDougall, N., Waddell, B., O'Riordan, J. I. Tags: Immunology (including allergy), Brain stem / cerebellum, Drugs: CNS (not psychiatric), Epilepsy and seizures, Infection (neurology), Stroke, Drugs misuse (including addiction), Connective tissue disease, Musculoskeletal syndromes Association of British Source Type: research

Cerebral Varicella Zoster Vasculopathy Sine Herpete: Atypical Ramsay-Hunt Syndrome Presentation in an Immunocompetent Patient (P6.258)
CONCLUSIONS:VZV CNS vasculopathy may present with atypical clinical and CSF characteristics. Patients with suspected CNS vasculitis without pathological confirmation should be tested for this treatable condition, regardless of their immune status.Disclosure: Dr. Gonzalez Otarula has nothing to disclose. Dr. Bruno has nothing to disclose. Dr. Pujol-Lereis has nothing to disclose. Dr. Ameriso has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Gonzalez Otarula, K., Bruno, V., Pujol-Lereis, V., Ameriso, S. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research

Spinal Cord Infarction as the Initial Presentation of Systemic Lupus Erythematosus (P2.077)
CONCLUSIONS:Aggressive therapy with high dose corticosteroids and intravenous cyclophosphamide followed by oral therapy may be a successful therapeutic approach to spinal cord infarcts secondary to systemic lupus erythematosus. Study Supported by: N/ADisclosure: Dr. Michael has nothing to disclose. Dr. Hayat has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Michael, A., Hayat, G. Tags: Neurological Consequences of Autoimmune Disease Source Type: research

Systemic lupus erythematosus associated with development of macrophage activation syndrome and disseminated aspergillosis
CONCLUSIONS: Four features of this case merit discussion, including the: 1) infrequent association of SLE with MAS; 2) short interval between SLE diagnosis and critical illness; 3) manifestation of fungal tracheobronchitis with airway obstruction; and 4) lack of response to antifungal treatment while receiving ECMO.PMID:37349668 | DOI:10.1007/s12630-023-02506-2
Source: Canadian Journal of Anaesthesia - June 22, 2023 Category: Anesthesiology Authors: Vorakamol Phoophiboon Paula Brown Karen E A Burns Source Type: research